These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8608049)

  • 21. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health Economics Unit achievements.
    Crott R; Neymark N
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S147-50. PubMed ID: 11858982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration and reimbursement of complementary and alternative medicine by managed care and insurance providers: 2000 update and cohort analysis.
    Pelletier KR; Astin JA
    Altern Ther Health Med; 2002; 8(1):38-9, 42, 44 passim. PubMed ID: 11795621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III prostate cancer prevention trials: are the costs justified?
    Thompson IM; Tangen CM; Klein EA; Lippman SM
    J Clin Oncol; 2005 Nov; 23(32):8161-4. PubMed ID: 16278467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incremental costs of enrolling cancer patients in clinical trials: a population-based study.
    Wagner JL; Alberts SR; Sloan JA; Cha S; Killian J; O'Connell MJ; Van Grevenhof P; Lindman J; Chute CG
    J Natl Cancer Inst; 1999 May; 91(10):847-53. PubMed ID: 10340904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04.
    Owen JB; Grigsby PW; Caldwell TM; Konski AA; Johnson DJ; Demas WF; Movsas B; Jones CU; Wasserman TH
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):633-9. PubMed ID: 11172943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Issues in the economic analysis of therapies for cancer pain.
    Portenoy RK
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):71-8. PubMed ID: 8608059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generalisation from phase III clinical trials: survival, quality of life, and health economics.
    Fayers PM; Hand DJ
    Lancet; 1997 Oct; 350(9083):1025-7. PubMed ID: 9329528
    [No Abstract]   [Full Text] [Related]  

  • 31. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials.
    Mauskopf J; Schulman K; Bell L; Glick H
    Pharmacoeconomics; 1996 Mar; 9(3):264-77. PubMed ID: 10160101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analyses in clinical trials for cooperative groups: operational considerations.
    Bennett CL; Waters TM
    Cancer Invest; 1997; 15(5):448-53. PubMed ID: 9316627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation and quality of life assessments in cancer clinical trials: the CHART Trial.
    Morris J; Goddard M
    Eur J Cancer; 1993; 29A(5):766-70. PubMed ID: 8471337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer Care Costs and Clinical Trials.
    Kelly D; Brady C; Sui J; Cronin E; O'Hare D; Waldron J; O'Mahony D; Power D; Bambury RM; O'Reilly S
    Ir Med J; 2017 Apr; 110(4):557. PubMed ID: 28665096
    [No Abstract]   [Full Text] [Related]  

  • 35. How much do phase III trials cost?
    Mullard A
    Nat Rev Drug Discov; 2018 Oct; 17(11):777. PubMed ID: 30374183
    [No Abstract]   [Full Text] [Related]  

  • 36. Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.
    Nghiem VT; Vaidya R; Lyman GH; Hershman DL; Ramsey SD; Unger JM
    Value Health; 2020 Dec; 23(12):1653-1661. PubMed ID: 33248521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy.
    Konski A; Bhargavan M; Owen J; Komaki R; Langer CJ; Gore E; Paulus R; Choy H; Bruner DW; Curran WJ
    J Radiat Oncol; 2018 Jun; 7(2):195-201. PubMed ID: 30559923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of using administrative claims data for cost-effectiveness analysis of a clinical trial.
    Konski A; Bhargavan M; Owen J; Paulus R; Cooper J; Fu KK; Ang K; Watkins-Bruner D
    J Med Econ; 2008; 11(4):611-23. PubMed ID: 19450071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic analysis of randomized, controlled trials.
    Lyman GH
    Curr Oncol Rep; 2001 Sep; 3(5):396-403. PubMed ID: 11489239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodological hurdles in conducting pharmacoeconomic analyses.
    Rizzo JD; Powe NR
    Pharmacoeconomics; 1999 Apr; 15(4):339-55. PubMed ID: 10537953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.